XPH: SPDR® S&P® Pharmaceuticals ETF

NAV

$43.29

as of Sep 23 2020

Base Currency

USD

Assets Under Management

$220.81 M

as of Sep 23 2020

Gross Expense Ratio

0.35%

Quick Links

Key Features

The SPDR^® S&P^® Pharmaceuticals ETF seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P^® Pharmaceuticals Select Industry^® Index (the "Index")
Seeks to provide exposure to the pharmaceuticals segment of the S&P TMI, which comprises the Pharmaceuticals sub-industry
Seeks to track a modified equal weighted index which provides the potential for unconcentrated industry exposure across large, mid and small cap stocks
Allows investors to take strategic or tactical positions at a more targeted level than traditional sector based investing

About this Benchmark

The S&P Pharmaceuticals Select Industry Index (the "Index") represents the pharmaceuticals segment of the S&P Total Market Index ("S&P TMI"). The S&P TMI is designed to track the broad U.S. equity market. The pharmaceuticals segment of the S&P TMI comprises the Pharmaceuticals sub-industry. The Index is one of twenty-one (21) of the S&P Select Industry Indices (the "Select Industry Indices"), each designed to measure the performance of a narrow sub-industry or group of sub-industries determined based on the Global Industry Classification Standard ("GICS").

Fund Information as of Sep 23 2020

Benchmark	Inception Date	Options Available	Gross Expense Ratio Gross Expense Ratio The fund's total annual operating expense ratio. It is gross of any fee waivers or expense reimbursements. It can be found in the fund's most recent prospectus.	Base Currency	Investment Manager	Management Team
S&P Pharmaceuticals Select Industry Index	Jun 16 2006	Yes	0.35%	USD	SSGA Funds Management, Inc.	Global Equity Beta Solutions

Benchmark	S&P Pharmaceuticals Select Industry Index
Inception Date	Jun 16 2006
Options Available	Yes
Gross Expense Ratio Gross Expense Ratio The fund's total annual operating expense ratio. It is gross of any fee waivers or expense reimbursements. It can be found in the fund's most recent prospectus.	0.35%
Base Currency	USD
Investment Manager	SSGA Funds Management, Inc.
Management Team	Global Equity Beta Solutions

Distributor	Distribution Frequency
State Street Global Advisors Funds Distributors, LLC	Quarterly

Distributor	State Street Global Advisors Funds Distributors, LLC
Distribution Frequency	Quarterly

Listing Information as of Sep 23 2020

Exchange	Listing Date	Trading Currency	Ticker	CUSIP	ISIN
NYSE ARCA EXCHANGE	Jun 23 2006	USD	XPH	78464A722	US78464A7220

Exchange	NYSE ARCA EXCHANGE
Listing Date	Jun 23 2006
Trading Currency	USD
Ticker	XPH
CUSIP	78464A722
ISIN	US78464A7220

Fund Characteristics as of Sep 23 2020

Est. 3-5 Year EPS Growth Estimated 3-5 Year EPS Growth Based on the underlying holdings of the fund. The actual earnings estimates for the underlying holdings are provided by FactSet, First Call, I/B/E/S Consensus, and Reuters and are used to calculate a mean 3-5 year EPS growth rate estimate.	Number of Holdings	Price/Book Ratio Price/Book Ratio The weighted harmonic average of closing market price divided by the most recent reported book value for each security in the fund's portfolio as calculated for the last twelve months.	Price/Earnings Ratio FY1 Price/Earnings Ratio FY1 The weighted harmonic average of current share price divided by the forecasted one year earnings per share for each security in the fund. Negative and positive outliers are included in the calculation.	Weighted Average Market Cap
13.04%	42	3.06	10.87	$54,725.45 M

Est. 3-5 Year EPS Growth Estimated 3-5 Year EPS Growth Based on the underlying holdings of the fund. The actual earnings estimates for the underlying holdings are provided by FactSet, First Call, I/B/E/S Consensus, and Reuters and are used to calculate a mean 3-5 year EPS growth rate estimate.	13.04%
Number of Holdings	42
Price/Book Ratio Price/Book Ratio The weighted harmonic average of closing market price divided by the most recent reported book value for each security in the fund's portfolio as calculated for the last twelve months.	3.06
Price/Earnings Ratio FY1 Price/Earnings Ratio FY1 The weighted harmonic average of current share price divided by the forecasted one year earnings per share for each security in the fund. Negative and positive outliers are included in the calculation.	10.87
Weighted Average Market Cap	$54,725.45 M

Index Characteristics as of Sep 23 2020

Est. 3-5 Year EPS Growth	Number of Holdings	Price/Cash Flow	Price/Earnings	Price/Earnings Ratio FY1
13.04%	42	9.96	18.98	10.87

Est. 3-5 Year EPS Growth	13.04%
Number of Holdings	42
Price/Cash Flow	9.96
Price/Earnings	18.98
Price/Earnings Ratio FY1	10.87

Index Statistics as of Sep 23 2020

	Average Size		Size Range
Weighted Average Market Cap	Mean	Median	Largest	Smallest
$54,726.98 M	$29,786.75 M	$1,626.61 M	$380,220.53 M	$374.34 M

Weighted Average Market Cap	$54,726.98 M
Average Size
Mean	$29,786.75 M
Median	$1,626.61 M
Size Range
Largest	$380,220.53 M
Smallest	$374.34 M

Yields as of Sep 22 2020

30 Day SEC Yield 30 Day SEC Yield (Also known as Standardized Yield) An annualized yield that is calculated by dividing the net investment income earned by the fund over the most recent 30-day period by the current maximum offering price.	30 Day SEC Yield (Unsubsidized) 30 Day SEC Yield (Unsubsidized) An annualized yield that is calculated by dividing the net investment income earned by the fund over the most recent 30-day period by the current maximum offering price that does not account for expense ratio waivers.	Fund Dividend Yield Fund Dividend Yield The sum of the most recent 12 dividends within the past 365 days divided by Net Asset Value per share, expressed as a percentage.	Index Dividend Yield Index Dividend Yield The weighted average of the underlyings' indicated annual dividend divided by price, expressed as a percentage.
0.43%	-	0.59%	0.76%

30 Day SEC Yield 30 Day SEC Yield (Also known as Standardized Yield) An annualized yield that is calculated by dividing the net investment income earned by the fund over the most recent 30-day period by the current maximum offering price.	0.43%
30 Day SEC Yield (Unsubsidized) 30 Day SEC Yield (Unsubsidized) An annualized yield that is calculated by dividing the net investment income earned by the fund over the most recent 30-day period by the current maximum offering price that does not account for expense ratio waivers.	-
Fund Dividend Yield Fund Dividend Yield The sum of the most recent 12 dividends within the past 365 days divided by Net Asset Value per share, expressed as a percentage.	0.59%
Index Dividend Yield Index Dividend Yield The weighted average of the underlyings' indicated annual dividend divided by price, expressed as a percentage.	0.76%

Fund Market Price as of Sep 23 2020

Bid/Ask Bid/Ask Mid Point (Also known as Mid Price) The price between the best price of the sellers for a trading unit of a given security and the best price of the buyer of a trading unit of a given security.	Closing Price Closing Price Market Price of last reported trade on the exchange.	Day High	Day Low	Exchange Volume (Shares) Exchange Volume (shares) Represents the volume of shares traded on the ETF's primary exchange throughout the previous business day.	Premium/Discount Premium/Discount to NAV Shows the comparison of the daily net asset value (NAV) and the Midpoint of the closing bid/ask for each of the funds calculated as ((4PM Bid/Ask - Closing NAV) / Closing NAV * 100)
$43.28	$43.32	$44.23	$43.27	21,697	-0.03%

Bid/Ask Bid/Ask Mid Point (Also known as Mid Price) The price between the best price of the sellers for a trading unit of a given security and the best price of the buyer of a trading unit of a given security.	$43.28
Closing Price Closing Price Market Price of last reported trade on the exchange.	$43.32
Day High	$44.23
Day Low	$43.27
Exchange Volume (Shares) Exchange Volume (shares) Represents the volume of shares traded on the ETF's primary exchange throughout the previous business day.	21,697
Premium/Discount Premium/Discount to NAV Shows the comparison of the daily net asset value (NAV) and the Midpoint of the closing bid/ask for each of the funds calculated as ((4PM Bid/Ask - Closing NAV) / Closing NAV * 100)	-0.03%

Premium Discount to Nav

Quarter

x axis: # of days

y axis: # Premium/Discount percentage

Fund Data

The above information is provided to show the comparison of the daily net asset value (NAV) and the Midpoint of the closing bid/ask for each of the funds.

Before investing, consider the funds' investment objectives, risks, charges and expenses. To obtain a prospectus or summary prospectus which contains this and other information, call 1-866-787-2257 download a prospectus or summary prospectus now, or talk to your financial advisor. Read it carefully before investing.

Fund Net Cash Amount as of Sep 23 2020

Net Cash Amount
-$237,828.53

Net Cash Amount

-$237,828.53

Fund Net Asset Value as of Sep 23 2020

NAV NAV The market value of a mutual fund's or ETFs total assets, minus liabilities, divided by the number of shares outstanding.	Shares Outstanding	Assets Under Management
$43.29	5.10 M	$220.81 M

NAV NAV The market value of a mutual fund's or ETFs total assets, minus liabilities, divided by the number of shares outstanding.	$43.29
Shares Outstanding	5.10 M
Assets Under Management	$220.81 M

Most Recent NAV / NAV History

Fund Performance

Fund Inception Date: Jun 16 2006
Performance Inception Date: Jun 19 2006

Performance

Month End Quarter End

as of Aug 31 2020

as of Jun 30 2020

	As Of	1 Month	QTD	YTD	1 Year	3 Year	5 Year	10 Year	Since Inception Jun 19 2006
Fund Before Tax
NAV	Aug 31 2020	3.82%	2.74%	-2.88%	25.76%	1.74%	-3.44%	10.59%	9.56%
Market Value	Aug 31 2020	3.81%	2.76%	-2.84%	25.87%	1.76%	-3.43%	10.58%	9.56%
S&P Pharmaceuticals Select Industry Index	Aug 31 2020	3.85%	2.80%	-2.85%	25.95%	1.89%	-3.29%	10.78%	9.75%
Fund After Tax
Return after Taxes on Distributions	Aug 31 2020	3.82%	2.74%	-3.02%	25.46%	1.56%	-4.10%	9.87%	8.98%
Return after Taxes on Distributions and Sale of Fund Shares	Aug 31 2020	2.26%	1.62%	-1.72%	15.31%	1.30%	-2.78%	8.56%	7.90%
S&P Pharmaceuticals Select Industry Index	Aug 31 2020	3.85%	2.80%	-2.85%	25.95%	1.89%	-3.29%	10.78%	9.75%

	As Of	1 Month	QTD	YTD	1 Year	3 Year	5 Year	10 Year	Since Inception Jun 19 2006
Fund Before Tax
NAV	Jun 30 2020	-0.12%	19.56%	-5.47%	9.18%	0.73%	-5.36%	10.65%	9.47%
Market Value	Jun 30 2020	-0.05%	19.54%	-5.45%	9.16%	0.73%	-5.37%	10.64%	9.46%
S&P Pharmaceuticals Select Industry Index	Jun 30 2020	-0.09%	19.67%	-5.49%	9.27%	0.86%	-5.22%	10.85%	9.66%
Fund After Tax
Return after Taxes on Distributions	Jun 30 2020	-0.18%	19.49%	-5.61%	8.92%	0.54%	-5.99%	9.93%	8.89%
Return after Taxes on Distributions and Sale of Fund Shares	Jun 30 2020	-0.07%	11.58%	-3.25%	5.49%	0.52%	-4.16%	8.63%	7.82%
S&P Pharmaceuticals Select Industry Index	Jun 30 2020	-0.09%	19.67%	-5.49%	9.27%	0.86%	-5.22%	10.85%	9.66%

Performance quoted represents past performance, which is no guarantee of future results. Investment return and principal value will fluctuate, so you may have a gain or loss when shares are sold. Current performance may be higher or lower than that quoted. Performance of an index is not illustrative of any particular investment. It is not possible to invest directly in an index.

Performance returns for periods of less than one year are not annualized. Performance is shown net of fees.

The market price used to calculate the Market Value return is the midpoint between the highest bid and the lowest offer on the exchange on which the shares of the Fund are listed for trading, as of the time that the Fund's NAV is calculated. If you trade your shares at another time, your return may differ.

Gross Expense Ratio: 0.35%

Top Holdings
Subject to change.

Top Holdings

Fund Top Holdingsas of Sep 23 2020

Index Top Holdingsas of Sep 23 2020

Fund Top Holdings as of Sep 23 2020

Name	Shares Held	Total Mkt Cap M	Weight
Horizon Therapeutics Public Limited Company	139,970	$16,866.09	5.06%
Royalty Pharma Plc Class A	256,055	$15,287.27	4.85%
Reata Pharmaceuticals Inc. Class A	97,541	$3,101.82	4.80%
Catalent Inc	119,389	$13,802.39	4.54%
Eli Lilly and Company	66,672	$143,288.83	4.52%
Jazz Pharmaceuticals Plc	72,175	$7,657.17	4.51%
Zoetis Inc. Class A	62,258	$75,704.80	4.49%
Bristol-Myers Squibb Company	167,375	$132,959.61	4.47%
Pfizer Inc.	273,731	$200,047.69	4.46%
Merck & Co. Inc.	116,873	$208,991.19	4.37%

Download All Holdings: Daily

Index Top Holdings as of Sep 23 2020

Name	Total Mkt Cap M	Weight
Horizon Therapeutics Public Limited Company	$16,866.09	5.06%
Royalty Pharma Plc Class A	$15,287.27	4.85%
Reata Pharmaceuticals Inc. Class A	$3,101.82	4.80%
Catalent Inc	$13,802.39	4.54%
Eli Lilly and Company	$143,288.83	4.53%
Jazz Pharmaceuticals Plc	$7,657.17	4.52%
Zoetis Inc. Class A	$75,704.80	4.50%
Bristol-Myers Squibb Company	$132,959.61	4.47%
Pfizer Inc.	$200,047.69	4.47%
Merck & Co. Inc.	$208,991.19	4.38%

Sub-Industry Allocation

Fund Sub-Industry Allocationas of Sep 23 2020

Index Sub-Industry Allocationas of Sep 23 2020

Fund Sub-Industry Allocation as of Sep 23 2020

Sector	Weight
Pharmaceuticals	100.00%

Index Sub-Industry Allocation as of Sep 23 2020

Sector	Weight
Pharmaceuticals	100.00%

Fund Documents

Tax Documents

Information & Schedules

Purchase Information

Buying and Selling ETFs

ETFs are flexible and easy to trade. Investors buy and sell them like stocks, typically through a brokerage account. Investors can also employ traditional stock trading techniques; including stop orders, limit orders, margin purchases, and short sales using ETFs. They are listed on major US Stock Exchanges.

ETFs are subject to risk similar to those of stocks including those regarding short-selling and margin account maintenance.

Ordinary brokerage commissions apply.

Fund Footnotes

In general, ETFs can be expected to move up or down in value with the value of the applicable index. Although ETF shares may be bought and sold on the exchange through any brokerage account, ETF shares are not individually redeemable from the Fund. Investors may acquire ETFs and tender them for redemption through the Fund in Creation Unit Aggregations only. Please see the prospectus for more details.

After-tax returns are calculated based on NAV using the historical highest individual federal marginal income tax rates and do not reflect the impact of state and local taxes. Actual after-tax returns depend on the investor's tax situation and may differ from those shown. The after-tax returns shown are not relevant to investors who hold their fund shares through tax-deferred arrangements such as 401(k) plans or individual retirement accounts.

Unless otherwise noted all information contained herein is that of the SPDR S&P Pharmaceuticals ETF.

Performance of an index is not illustrative of any particular investment. It is not possible to invest directly in an index.

Holdings and sectors shown are as of the date indicated and are subject to change. This information should not be considered a recommendation to invest in a particular sector or to buy or sell any security shown. It is not known whether the sectors or securities shown will be profitable in the future.

As with all stocks, you may be required to deposit more money or securities into your margin account if the equity, including the amount attributable to your ETF shares, declines.

The S&P Select Industry Index series is designed to measure the performance of narrow GICS (Global Industry Classification S&Standard) sub-industries. The S&P Pharmaceuticals Select Industry Index is an equal-weighted index that draws constituents from the pharmaceuticals segment of the S&P TMI. Liquidity and market capitalization screens are applied to the index to ensure investability.

SPDR® S&P® Pharmaceuticals ETF XPH

Important Risk Disclosure

Key Features

About this Benchmark

Fund Information as of Sep 23 2020

Listing Information as of Sep 23 2020

Fund Characteristics as of Sep 23 2020

Index Characteristics as of Sep 23 2020

Index Statistics as of Sep 23 2020

Yields as of Sep 22 2020

Fund Market Price as of Sep 23 2020

Premium Discount to Nav

Fund Net Cash Amount as of Sep 23 2020

Fund Net Asset Value as of Sep 23 2020

Fund Performance

Top Holdings
Subject to change.

Fund Top Holdings as of Sep 23 2020

Index Top Holdings as of Sep 23 2020

Sub-Industry Allocation

Fund Sub-Industry Allocation as of Sep 23 2020

Index Sub-Industry Allocation as of Sep 23 2020

Purchase Information

SPDR® S&P® Pharmaceuticals ETF XPH

Important Risk Disclosure

Key Features

About this Benchmark

Fund Information as of Sep 23 2020

Listing Information as of Sep 23 2020

Fund Characteristics as of Sep 23 2020

Index Characteristics as of Sep 23 2020

Index Statistics as of Sep 23 2020

Yields as of Sep 22 2020

Fund Market Price as of Sep 23 2020

Premium Discount to Nav

Fund Net Cash Amount as of Sep 23 2020

Fund Net Asset Value as of Sep 23 2020

Fund Performance

Top HoldingsSubject to change.

Fund Top Holdings as of Sep 23 2020

Index Top Holdings as of Sep 23 2020

Sub-Industry Allocation

Fund Sub-Industry Allocation as of Sep 23 2020

Index Sub-Industry Allocation as of Sep 23 2020

Purchase Information

Top Holdings
Subject to change.